ArticleBioMed research international2014
Expression of neuroendocrine markers in different molecular subtypes of breast carcinoma.
Article in BioMed research international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 47 citations in OpenAlex.
- Primary large cell neuroendocrine carcinoma of the breast with metastasis in the lymph nodes: a case report and literature review.Frontiers in oncology · 2026Article
- Case Report: Neuroendocrine carcinoma of the breast: a review of the literature and illustration of six cases.Frontiers in medicine · 2025Article
- A morphological and immunohistochemical study of ductal carcinoma in situ, invasive breast carcinoma of no special type, and mucinous carcinoma of the breast in comparison with solid papillary carcinoma regarding neuroendocrine marker expression.Virchows Archiv : an international journal of pathology · 2024Article
- Clinicopathological Characteristics and Prognostic Profiles of Breast Carcinoma with Neuroendocrine Features.Life (Basel, Switzerland) · 2023Article
- Genetic and immunohistochemical profiling of small cell and large cell neuroendocrine carcinomas of the breast.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2022Article
- The Clinical Significance of Neuroendocrine Features in Invasive Breast Carcinomas.The oncologist · 2020Article
- Review
- Advanced Approaches to Breast Cancer Classification and Diagnosis.Frontiers in pharmacology · 2020Review
- The rare entity of bilateral and unilateral neuroendocrine metastases to the breast: a case series and literature review.Ecancermedicalscience · 2020Article
- Neuroendocrine Carcinomas of the Canine Mammary Gland: Histopathological and Immunohistochemical Characteristics.Frontiers in veterinary science · 2020Article
- Pathologic differential diagnosis of metastatic carcinoma in the liver.Clinical and molecular hepatology · 2019Review
- Primary small cell carcinoma of the breast: a case report.Journal of medical case reports · 2017Article
- Article
- Primary neuroendocrine breast carcinomas are associated with poor local control despite favourable biological profile: a retrospective clinical study.BMC cancer · 2017Article
- Immunohistochemical Expression of CDIranian journal of otorhinolaryngology · 2016Article
- [New prognostic and predictive markers for breast cancer].Der Pathologe · 2016Review
- Doublecortin-like kinase 1 expression associates with breast cancer with neuroendocrine differentiation.Oncotarget · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCarcinomas of the breast with neuroendocrine features are incorporated in the World Health Organization classification since 2003 and include well-differentiated neuroendocrine tumors, poorly differentiated neuroendocrine carcinomas/small cell carcinomas, and invasive breast carcinomas with neuroendocrine differentiation. Neuroendocrine differentiation is known to be more common in certain low-grade histologic special types and has been shown to mainly cluster to the molecular (intrinsic) luminal A subtype.
methodsWe analyzed the frequency of neuroendocrine differentiation in different molecular subtypes of breast carcinomas of no histologic special type using immunohistochemical stains with specific neuroendocrine markers (chromogranin A and synaptophysin).
resultsWe found neuroendocrine differentiation in 20% of luminal B-like carcinomas using current WHO criteria (at least 50% of tumor cells positive for synaptophysin or chromogranin A). In contrast, no neuroendocrine differentiation was seen in luminal A-like, HER2 amplified and triple-negative carcinomas. Breast carcinomas with neuroendocrine differentiation presented with advanced stage disease and showed aggressive behavior.
conclusionsWe conclude that neuroendocrine differentiation is more common than assumed in poorly differentiated luminal B-like carcinomas. Use of specific neuroendocrine markers is thus encouraged in this subtype to enhance detection of neuroendocrine differentiation and hence characterize the biological and therapeutic relevance of this finding in future studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.